Aripiprazole

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Therapy, Addiction, Paroxetine, Anxiety, DMT, Mental health, SP, Imipramine, Artificial intelligence, Tri, Serotonin, BPP, Sleep, MT1, HTR, Aripiprazole, Fenfluramine, MDMA, Trazodone, Human, Mammal, Patient, Hallucination, Melatonin, DSM-IV codes, Plasma, ADHD, Literature, Research, Nefazodone, Mouse, Depression, Pharmaceutical industry

“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.

Key Points: 
  • “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
  • Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
  • For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .

Keystone Lab Announces Addition of Tianeptine to Testing Menu

Retrieved on: 
Tuesday, February 13, 2024
Clozapine, Anxiety, Opioid use disorder, Modafinil, Diphenhydramine, FDA, Pain, MC5, Aripiprazole, Food and Drug Administration, Forensic toxicology, Loperamide, Death, Keystone, Neptune, Abdominal pain, Patient, CLIA, Urine, Tianeptine, Depression

ASHEVILLE, N.C., Feb. 13, 2024 /PRNewswire/ -- Keystone Lab , a dual-CAP accredited and CLIA certified lab based in Asheville, NC, has officially added tianeptine to its in-house urine clinical toxicology menu.

Key Points: 
  • ASHEVILLE, N.C., Feb. 13, 2024 /PRNewswire/ -- Keystone Lab , a dual-CAP accredited and CLIA certified lab based in Asheville, NC, has officially added tianeptine to its in-house urine clinical toxicology menu.
  • Keystone provides clinical and forensic toxicology testing services throughout the southeastern U.S. and is one of few labs in the southeast to offer testing for tianeptine.
  • In addition to tianeptine and its metabolite, tianeptine metabolite MC5, Keystone has also added clozapine, N-desmethylclozapine, aripiprazole, aripiprazole metabolite OPC-3373, modafinil, diphenhydramine, loperamide, and 7OH-mitragynine to its in-house menu.
  • "By adding tianeptine testing in-house, Keystone is able to listen to its clients and provide the best service possible to their patients."

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

Retrieved on: 
Monday, May 22, 2023
Volunteering, Human, Central nervous system, Metabolism, Schizophrenia, American Society for Pharmacology and Experimental Therapeutics, New Drug Application, PME, NDA, CYP3A, Schizoaffective disorder, SAD, Cmax, Experiment, CNS, Clozapine, CYP3A4, Risperidone, Plasma, Aripiprazole, Animal, DSM-IV codes, Patient, Phenytoin, Itraconazole, Mouse, State, Glucuronic acid, Pharmacology, Lurasidone, Society, Brexpiprazole, Cariprazine, Safety, ASPET, Vaccine, Pharmaceutical industry, Brilaroxazine

CUPERTINO, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023 annual meeting took place in St. Louis, Missouri, USA, May 18-21, 2023. The ASPET posters are available at revivapharma.com/publications. Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.

Key Points: 
  • Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.
  • “These data support the concomitant use of brilaroxazine with other medications metabolized by CYP3A4 as most schizophrenia patients take multiple concomitant medications.
  • As part of the required clinical studies for New Drug Application (NDA), the drug-drug interactions between brilaroxazine with a strong CYP3A4 inhibitor (itraconazole) and inducer (phenytoin) were evaluated.
  • Brilaroxazine single dose co-administered with phenytoin at steady-state resulted in decrease of ~33%, 57% and 54% in brilaroxazine Cmax, AUC0-t, and AUC0∞, respectively.

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

Retrieved on: 
Friday, April 28, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Maintenance, Schizophrenia, New Drug Application, NDA, Bipolar I disorder, Multimedia, Plasma, Aripiprazole, Patient, Trial of the century, R, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Safety, Syringe, Pharmaceutical industry, Lundbeck

View the full release here: https://www.businesswire.com/news/home/20230427006070/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230427006070/en/
    Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death.
  • ABILIFY ASIMTUFII is not approved for the treatment of patients with dementia-related psychosis.
  • ABILIFY ASIMTUFII, a long-acting injectable, provides continuous delivery of medication and can maintain therapeutic plasma concentrations, which may help those living with schizophrenia and bipolar I disorder.
  • We hope that the use of ABILIFY ASIMTUFII in treatment plans will have a positive impact on those living with schizophrenia or bipolar I disorder,” said Johan Luthman, executive vice president, R&D, Lundbeck.

Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder

Retrieved on: 
Tuesday, April 4, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Maintenance, Lundbeck, Schizophrenia, Medication, Medicine, DSM-IV codes, Bipolar I disorder, Multimedia, Weight gain, Plasma, Aripiprazole, Patient, CNS Drugs (journal), Safety, Pharmaceutical industry

Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational long-acting injectable, aripiprazole 2-month, ready-to-use 960 mg, offers comparable tolerability, safety and therapeutic plasma levels as aripiprazole 1-month, ready-to-use 400 mg, currently approved in adult patients for the treatment of schizophrenia or the maintenance treatment of bipolar I disorder (BP-I).

Key Points: 
  • Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational long-acting injectable, aripiprazole 2-month, ready-to-use 960 mg, offers comparable tolerability, safety and therapeutic plasma levels as aripiprazole 1-month, ready-to-use 400 mg, currently approved in adult patients for the treatment of schizophrenia or the maintenance treatment of bipolar I disorder (BP-I).
  • View the full release here: https://www.businesswire.com/news/home/20230404005432/en/
    The 32-week randomized trial evaluated the safety, tolerability and pharmacokinetic profile of aripiprazole 2-month compared to aripiprazole 1-month, among 266 eligible patients.
  • Results showed aripiprazole 2-month is a well-tolerated maintenance treatment for schizophrenia and BP-I and maintains consistent therapeutic plasma levels for at least two months as compared to aripiprazole 1-month plasma levels following repeated monthly dosing.
  • The most frequently reported adverse events (>10% in either treatment group) were increased weight gain (22.7% for aripiprazole 2-month versus 20.9% for aripiprazole 1-month) and injection site pain (18.2% for aripiprazole 2-month versus 9.0% for aripiprazole 1-month).

Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Pharmaceutical, Health, ODT, Ipilimumab, Aripiprazole, Therapy, Shirin David, Shareholder, University, Bachelor of Science, NS3, Bristol Myers Squibb, Nivolumab, Drug development, Acquisition, Yale school, CGRP, Neurology, Calcitonin, Physiology, Daclatasvir, Wake Forest School of Medicine, Medical director, Sale, Yale School of Medicine, Psychiatry, NS5A, DNAA, Pharmaceutical industry, Pfizer, Neuroscience

(RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023.

Key Points: 
  • (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023.
  • The company also announced that long-standing director Philip Vickers has decided that he will be retiring from the Board effective immediately prior to the company’s 2023 Annual Meeting of Stockholders.
  • “His appointment comes at a dynamic time for Revance as we accelerate our commercial growth in aesthetics and look to advance our significant opportunity in therapeutics.
  • Previously, Dr. Coric was the Group Director, Neuroscience and Oncology Global Clinical Research, and Medical Director, Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company.

Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

Retrieved on: 
Tuesday, January 3, 2023
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., ACAD, Psychosis, Acadia Pharmaceuticals, Risperidone, Clozapine, CI, Delusion, Death, PDP, Patient, Mortality, Medical Affairs Bureau, PS, Particle-size distribution, Physician, FDA, Hallucination, LTC, Observational study, Long-term care, Aripiprazole, Drug Safety, Senior, HR, SNF, Medicare, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups.
  • NUPLAZID is the only medication approved by the U.S. FDA for the treatment of hallucinations and delusions associated with PDP.
  • “We were encouraged by this large, real-world study showing a lower mortality risk in patients with PDP after initiation of NUPLAZID, compared to other atypical antipsychotics.
  • After matching the two cohorts using propensity scores (PS), there were 2,891 patients in each of the NUPLAZID and comparator cohorts.

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Retrieved on: 
Tuesday, November 29, 2022
Aripiprazole, Mental health, University, Otsuka Pharmaceutical, Patient, Business development, Annual report, Public expenditure, Anxiety, Thought, World Health Organization, Drug development, CNS, Security (finance), Depression, Therapy, Addiction, Master of Philosophy, Pharmaceutical industry, Tolvaptan

NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) --  atai Life Sciences N.V., (NASDAQ: ATAI) (“atai” or the “Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company’s Chief Business Officer, effective today.

Key Points: 
  • NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (NASDAQ: ATAI) (atai or the Company), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Companys Chief Business Officer, effective today.
  • Dr. Kirpekar joins atai after more than eight years at Otsuka Pharmaceutical Co., Ltd., most recently as the Head of Business Development and Co-chair of the Global Business Development Committee.
  • Dr. Kirpekar is a trained physician and holds an MPhil from the University of Cambridge (where he is subsequently an honorary lecturer).
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2031

Retrieved on: 
Friday, November 25, 2022
FDA, ASD, Clinical trial, Autism spectrum, Communication, Johnson & Johnson, Investment, Irritability, Population Health Management, Autism, Risperidone, Aripiprazole, Ōtsuka, Clinical formulation, IIB, Therapy, Growth, Epidemiology, Otsuka Pharmaceutical, Pharmaceutical industry, Retail, Marketing, Drive

View original content:https://www.prnewswire.com/news-releases/autism-spectrum-disorder-market...

Key Points: 
  • These are expected to be the main driver of growth in the ASD market across the 7MM.
  • - The analyst expects Johnson and Johnsons JNJ-5279 to become the top-selling drug in the ASD market with sales of $655.9 Million in 2031.
  • - Since most drugs used for ASD are used off-label, there are very few companies with a strong presence in the ASD market.
  • - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ASD therapeutics market.

CRIO Welcomes Dr. Margaretta Nyilas to its Board of Directors

Retrieved on: 
Thursday, November 3, 2022
Board, Knowledge, Clinical data management, Bristol Myers Squibb, Clinical trial, Boston Millennia Partners, CEO, Technology, Heart, Aripiprazole, Board of directors, CRIO, Cros, Medicine, Therapy, Norwest Venture Partners, ESourcing Capability Model, Otsuka Pharmaceutical, JD, Margaretta, Brexpiprazole, Pharmaceutical industry

BOSTON, Nov. 3, 2022 /PRNewswire/ --CRIO, the industry's leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately.

Key Points: 
  • BOSTON, Nov. 3, 2022 /PRNewswire/ --CRIO, the industry's leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately.
  • She joins CRIO as its first independent director, where she will bring her unique blend of knowledge in clinical operations, technology and medicine.
  • "We couldn't be happier with Margaretta joining the Board," says Raymond Nomizu, JD, CEO and co-founder at CRIO.
  • Dr. Nyilas joins CRIO board members Sankesh Abbhi, formerly CEO of ArisGlobal; Tom Peterson, Venture Partner at Rally Ventures; and CEO, Raymond Nomizu.